Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G

Southern Medical Journal

Volumn 103, Issue 9, 2010, Pages 856-863

  Berger, Melvin ^a   Murphy, Elyse ^a   Riley, Patty ^a   Bergman, Garrett E ^a  

^a CSL Behring LLC   (United States)

Author keywords

bacterial infection rates; immunoglobulin; primary immunodeficiency disorders; quality of life; serum iGG; subcutaneous immune globulin (SCIG)

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR;

ACUTE SINUSITIS; ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BRONCHITIS; CHILD; CROHN DISEASE; DIZZINESS; DRUG INDUCED HEADACHE; FEMALE; HEART INFARCTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION RATE; INJECTION SITE REACTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRESCHOOL CHILD; QUALITY OF LIFE; SCHOOL CHILD; SELF CARE; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; BLOOD; CLINICAL TRIAL; DRUG ERUPTION; DRUG SELF ADMINISTRATION; HEALTH STATUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFECTION; MEDICAL LEAVE; MENTAL HEALTH; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DRUG ERUPTIONS; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS; INFECTION; INFUSIONS, SUBCUTANEOUS; MALE; MENTAL HEALTH; MIDDLE AGED; QUALITY OF LIFE; SELF ADMINISTRATION; SICK LEAVE;

EID: 77956392941     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181eba6ea     Document Type: Article

References (17)

1. Buckley R, ed. Diagnostic and Clinical Care Guidelines for Primary Immunodeficiency Diseases. Towson, MD: Immune Dificiency Foundation; 2008.
2. Eades-Perner AM, Gathmann B, Knerr V, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2004-2006. Clin Exp Immunol 2007;147:306-312.
3. Björkander J, Chapel H, Spickett G. Comparison of the efficacy and safety of immunoglobulin given subcutaneously versus intravenous im-munoglobulin in the prevention of infections in patients with primary antibody deficiency syndromes. Mol Immunol 1998;35:11-12.
4. Cunningham-Rundles C, Siegal FP, Smithwick EM, et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 1984;101:435-439.
5. Lederman HM, Roifman CM, Lavi S, et al. Corticosteroids for prevention of adverse reactions to intravenous immune globulin infusions in hypogammaglobulinemic patients. Am J Med 1986;81:443-446.
6. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004;112:1-7.
7. Gardulf A, Hammarström L, Smith CI. Home treatment of hypogam-maglobulinemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991;338:162-166.
8. Gardulf A, Andersen V, Björkander J, et al. Subcutaneous immunoglob-ulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995;345:365-369.
9. Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000;20:94-100.
10. Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006;26:65-72.
11. Nicolay U, Haag S, Eichmann F, et al. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immuno-globulin replacement therapy. Qual Life Res 2005;14:1683-1691.
12. Gardulf A, Borte M, Ochs HD, et al; Vivaglobin Clinical Study Group. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol 2008;126:81-88.
13. Guidance for Industry: Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency. Available at: http://www.fda.gov/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ ucm072130.htm. Accessed July 6, 2010.
14. Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 2004;114:936-942.
15. Ochs HD, Gupta S, Kiessling P, et al; Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26:265-273.
16. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodefi-ciencies-a prospective, multi-national study. J Clin Immunol 2006;26:177-185.
17. Desai SH, Chouksey A, Poll J, et al. A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously. J Allergy Clin Immunol 2009;124:854-856.